Research programme: TNF-alpha inhibitors - Borean Pharma

Drug Profile

Research programme: TNF-alpha inhibitors - Borean Pharma

Alternative Names: C-type lectin domain-derived TNF antagonist; CTLD-derived trimeric TNF antagonist; DC001-c; DC001-e

Latest Information Update: 03 Dec 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Borean Pharma
  • Class Recombinant proteins
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 09 Dec 2005 Borean Pharma has established proof of concept with their TNF-α antagonist for rheumatoid arthritis
  • 16 Aug 2005 This programme is still in active development - (BIO-2005)
  • 23 Feb 2004 Borean Pharma's TNF-α antagonists programme is available for licensing (http://www.boreanpharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top